Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes
The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Płucienniczak Andrzej Wojtowicz-Krawiec Anna Zieliński Marcin Borowicz Piotr Płucienniczak Graźyna Pawlukowiec Tomasz Pawłowska Monika Antosik Jarosław Kęsik-Brodacka Malgorzata Stępniewski Jacek Łukasiewicz Natalia Bernat Justyna Pstrzoch Jacek Kurzynoga Dariusz Sokołowska Iwona Głąbski Tadeusz Bogiel Monika Stadnik Dorota Cecuda-Adamczewska Violetta Mikołajczyk Jerzy Mikiewicz-Syguła Diana Tejchman-Małecka Boźena |
| description | The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterized by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called "sawteeth effect", during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g. night hypoglycaemias, because truly peakless, long-acting insulin should reproduce correct endogenous insulin secretion in the therapy, as is provided by a healthy pancreas at a proper and constant 24 hours level. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US9585942B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US9585942B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US9585942B23</originalsourceid><addsrcrecordid>eNqNjsFuwkAMRHPpAZX-gz-AXkKR4ApqBWfaMzK7k2SlzXq1doT4Qb6rSdVecurJY_uNZhbV45R0iCERJ47SDiApFEwpd1x6dhgsOI7xTuwcsvE1gpSjrWYEOemzaLAgiW7BOspFoqQWnqxD4fwDEpoGbnQPOkY104vCrMKKvCi3oB7WiR_v_k9OjgK2HsmmxQe-wqDL6qnhqHj5nc8Vfbx_Ho6vyHKB5rFmgl2-zrvNdrN7q_f1-h_IN0WzZBY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes</title><source>esp@cenet</source><creator>Płucienniczak Andrzej ; Wojtowicz-Krawiec Anna ; Zieliński Marcin ; Borowicz Piotr ; Płucienniczak Graźyna ; Pawlukowiec Tomasz ; Pawłowska Monika ; Antosik Jarosław ; Kęsik-Brodacka Malgorzata ; Stępniewski Jacek ; Łukasiewicz Natalia ; Bernat Justyna ; Pstrzoch Jacek ; Kurzynoga Dariusz ; Sokołowska Iwona ; Głąbski Tadeusz ; Bogiel Monika ; Stadnik Dorota ; Cecuda-Adamczewska Violetta ; Mikołajczyk Jerzy ; Mikiewicz-Syguła Diana ; Tejchman-Małecka Boźena</creator><creatorcontrib>Płucienniczak Andrzej ; Wojtowicz-Krawiec Anna ; Zieliński Marcin ; Borowicz Piotr ; Płucienniczak Graźyna ; Pawlukowiec Tomasz ; Pawłowska Monika ; Antosik Jarosław ; Kęsik-Brodacka Malgorzata ; Stępniewski Jacek ; Łukasiewicz Natalia ; Bernat Justyna ; Pstrzoch Jacek ; Kurzynoga Dariusz ; Sokołowska Iwona ; Głąbski Tadeusz ; Bogiel Monika ; Stadnik Dorota ; Cecuda-Adamczewska Violetta ; Mikołajczyk Jerzy ; Mikiewicz-Syguła Diana ; Tejchman-Małecka Boźena</creatorcontrib><description>The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterized by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called "sawteeth effect", during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g. night hypoglycaemias, because truly peakless, long-acting insulin should reproduce correct endogenous insulin secretion in the therapy, as is provided by a healthy pancreas at a proper and constant 24 hours level.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170307&DB=EPODOC&CC=US&NR=9585942B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170307&DB=EPODOC&CC=US&NR=9585942B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Płucienniczak Andrzej</creatorcontrib><creatorcontrib>Wojtowicz-Krawiec Anna</creatorcontrib><creatorcontrib>Zieliński Marcin</creatorcontrib><creatorcontrib>Borowicz Piotr</creatorcontrib><creatorcontrib>Płucienniczak Graźyna</creatorcontrib><creatorcontrib>Pawlukowiec Tomasz</creatorcontrib><creatorcontrib>Pawłowska Monika</creatorcontrib><creatorcontrib>Antosik Jarosław</creatorcontrib><creatorcontrib>Kęsik-Brodacka Malgorzata</creatorcontrib><creatorcontrib>Stępniewski Jacek</creatorcontrib><creatorcontrib>Łukasiewicz Natalia</creatorcontrib><creatorcontrib>Bernat Justyna</creatorcontrib><creatorcontrib>Pstrzoch Jacek</creatorcontrib><creatorcontrib>Kurzynoga Dariusz</creatorcontrib><creatorcontrib>Sokołowska Iwona</creatorcontrib><creatorcontrib>Głąbski Tadeusz</creatorcontrib><creatorcontrib>Bogiel Monika</creatorcontrib><creatorcontrib>Stadnik Dorota</creatorcontrib><creatorcontrib>Cecuda-Adamczewska Violetta</creatorcontrib><creatorcontrib>Mikołajczyk Jerzy</creatorcontrib><creatorcontrib>Mikiewicz-Syguła Diana</creatorcontrib><creatorcontrib>Tejchman-Małecka Boźena</creatorcontrib><title>Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes</title><description>The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterized by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called "sawteeth effect", during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g. night hypoglycaemias, because truly peakless, long-acting insulin should reproduce correct endogenous insulin secretion in the therapy, as is provided by a healthy pancreas at a proper and constant 24 hours level.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjsFuwkAMRHPpAZX-gz-AXkKR4ApqBWfaMzK7k2SlzXq1doT4Qb6rSdVecurJY_uNZhbV45R0iCERJ47SDiApFEwpd1x6dhgsOI7xTuwcsvE1gpSjrWYEOemzaLAgiW7BOspFoqQWnqxD4fwDEpoGbnQPOkY104vCrMKKvCi3oB7WiR_v_k9OjgK2HsmmxQe-wqDL6qnhqHj5nc8Vfbx_Ho6vyHKB5rFmgl2-zrvNdrN7q_f1-h_IN0WzZBY</recordid><startdate>20170307</startdate><enddate>20170307</enddate><creator>Płucienniczak Andrzej</creator><creator>Wojtowicz-Krawiec Anna</creator><creator>Zieliński Marcin</creator><creator>Borowicz Piotr</creator><creator>Płucienniczak Graźyna</creator><creator>Pawlukowiec Tomasz</creator><creator>Pawłowska Monika</creator><creator>Antosik Jarosław</creator><creator>Kęsik-Brodacka Malgorzata</creator><creator>Stępniewski Jacek</creator><creator>Łukasiewicz Natalia</creator><creator>Bernat Justyna</creator><creator>Pstrzoch Jacek</creator><creator>Kurzynoga Dariusz</creator><creator>Sokołowska Iwona</creator><creator>Głąbski Tadeusz</creator><creator>Bogiel Monika</creator><creator>Stadnik Dorota</creator><creator>Cecuda-Adamczewska Violetta</creator><creator>Mikołajczyk Jerzy</creator><creator>Mikiewicz-Syguła Diana</creator><creator>Tejchman-Małecka Boźena</creator><scope>EVB</scope></search><sort><creationdate>20170307</creationdate><title>Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes</title><author>Płucienniczak Andrzej ; Wojtowicz-Krawiec Anna ; Zieliński Marcin ; Borowicz Piotr ; Płucienniczak Graźyna ; Pawlukowiec Tomasz ; Pawłowska Monika ; Antosik Jarosław ; Kęsik-Brodacka Malgorzata ; Stępniewski Jacek ; Łukasiewicz Natalia ; Bernat Justyna ; Pstrzoch Jacek ; Kurzynoga Dariusz ; Sokołowska Iwona ; Głąbski Tadeusz ; Bogiel Monika ; Stadnik Dorota ; Cecuda-Adamczewska Violetta ; Mikołajczyk Jerzy ; Mikiewicz-Syguła Diana ; Tejchman-Małecka Boźena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US9585942B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2017</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Płucienniczak Andrzej</creatorcontrib><creatorcontrib>Wojtowicz-Krawiec Anna</creatorcontrib><creatorcontrib>Zieliński Marcin</creatorcontrib><creatorcontrib>Borowicz Piotr</creatorcontrib><creatorcontrib>Płucienniczak Graźyna</creatorcontrib><creatorcontrib>Pawlukowiec Tomasz</creatorcontrib><creatorcontrib>Pawłowska Monika</creatorcontrib><creatorcontrib>Antosik Jarosław</creatorcontrib><creatorcontrib>Kęsik-Brodacka Malgorzata</creatorcontrib><creatorcontrib>Stępniewski Jacek</creatorcontrib><creatorcontrib>Łukasiewicz Natalia</creatorcontrib><creatorcontrib>Bernat Justyna</creatorcontrib><creatorcontrib>Pstrzoch Jacek</creatorcontrib><creatorcontrib>Kurzynoga Dariusz</creatorcontrib><creatorcontrib>Sokołowska Iwona</creatorcontrib><creatorcontrib>Głąbski Tadeusz</creatorcontrib><creatorcontrib>Bogiel Monika</creatorcontrib><creatorcontrib>Stadnik Dorota</creatorcontrib><creatorcontrib>Cecuda-Adamczewska Violetta</creatorcontrib><creatorcontrib>Mikołajczyk Jerzy</creatorcontrib><creatorcontrib>Mikiewicz-Syguła Diana</creatorcontrib><creatorcontrib>Tejchman-Małecka Boźena</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Płucienniczak Andrzej</au><au>Wojtowicz-Krawiec Anna</au><au>Zieliński Marcin</au><au>Borowicz Piotr</au><au>Płucienniczak Graźyna</au><au>Pawlukowiec Tomasz</au><au>Pawłowska Monika</au><au>Antosik Jarosław</au><au>Kęsik-Brodacka Malgorzata</au><au>Stępniewski Jacek</au><au>Łukasiewicz Natalia</au><au>Bernat Justyna</au><au>Pstrzoch Jacek</au><au>Kurzynoga Dariusz</au><au>Sokołowska Iwona</au><au>Głąbski Tadeusz</au><au>Bogiel Monika</au><au>Stadnik Dorota</au><au>Cecuda-Adamczewska Violetta</au><au>Mikołajczyk Jerzy</au><au>Mikiewicz-Syguła Diana</au><au>Tejchman-Małecka Boźena</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes</title><date>2017-03-07</date><risdate>2017</risdate><abstract>The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterized by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called "sawteeth effect", during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g. night hypoglycaemias, because truly peakless, long-acting insulin should reproduce correct endogenous insulin secretion in the therapy, as is provided by a healthy pancreas at a proper and constant 24 hours level.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US9585942B2 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A34%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=P%C5%82ucienniczak%20Andrzej&rft.date=2017-03-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS9585942B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |